Author | Cornelis M. van Tilburg, MD, PhD | OncLive

Author | Cornelis M. van Tilburg, MD, PhD

Articles

Dr. van Tilburg on Larotrectinib in TRK+ Pediatric Cancers

July 02, 2019

Video

Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.

x